预约演示
更新于：2024-12-31
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2024-12-31
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
45
项与 盐酸尼卡地平 相关的临床试验NCT03184155
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
NCT06093893
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery
ChiCTR2400085752
Clinical study of the effect of nicardipine atropine pretreatment on hemodynamic changes during the treatment of trigeminal neuralgia by percutaneous microballoon compression
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
8,888
项与 盐酸尼卡地平 相关的文献（医药）2024-12-31PHARMACEUTICAL BIOLOGY
Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipine
Article
作者: Chen, Dongxin ; Shen, Yuxin ; Chen, Xiaohai ; Liu, Ya-nan ; Xia, Hailun ; Chen, Jie ; Xu, Ren-ai
CONTEXT:
Almonertinib is primarily metabolized by CYP3A4, so it could interact with a variety of drugs metabolized by CYP3A4, leading to the changes of systemic exposure.
OBJECTIVE:
For the purpose of this experiment, an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay with accuracy and simplicity was optimized and fully validated for the simultaneous quantitative determination of almonertinib and its metabolite HAS-719, and drug-drug interactions (DDI) between almonertinib and nicardipine in vivo and in vitro was researched.
MATERIALS AND METHODS:
Detection of analytes was achieved by UPLC-MS/MS coupled with multiple reaction monitoring (MRM) in the positive ion mode with ion transitions of m/z 526.01 → 72.04 for almonertinib, m/z 512.18 → 455.08 for HAS-719 and m/z 447.16 → 128.11 for IS, respectively.
RESULTS:
There was favourable linearity in the 0.5-200 ng/mL calibration range for almonertinib and 0.5-100 ng/mL for HAS-719. The lower limit of quantification (LLOQ) for both analytes was 0.5 ng/mL. The precision, accuracy, stability, matrix effect and extraction recovery required for methodological validation were consistent with the requirements of FDA guideline. Then, the UPLC-MS/MS assay was employed successfully on the interactions of almonertinib and nicardipine in vivo and in vitro. The half-maximal inhibitory concentration (IC50) was 1.19 μM in rat liver microsomes (RLM), where nicardipine inhibited the metabolism of almonertinib with a mixed inhibitory mechanism. In pharmacokinetic experiments of rats, it was observed that nicardipine could significantly alter the pharmacokinetic profiles of almonertinib, including AUC(0-∞), AUC(0-t) and Cmax, but had no effect on the metabolism of HAS-719.
CONCLUSION:
According to the findings, it was indicated that nicardipine could inhibit the metabolism of almonertinib in vitro and in vivo.
2024-12-31Hypertension in pregnancy
Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review
Review
作者: Jiang, Ruoan ; Li, Na ; Wang, Ting ; Yao, Yingsha ; Xu, Ting
BACKGROUND:
Preeclampsia (PE) is a pregnancy disorder that represents a major cause of maternal and perinatal morbidity and mortality.
METHODS:
This network meta-analysis was registered with PROSPERO. We searched the PubMed, ClinicalTrials.gov. and Embase databases for studies published from inception to the 31st of March 2023. RevMan5.3 software provided by the Cochrane Collaboration was used for direct meta-analysis (DMA) statistical analysis. Funnel maps, network meta-analysis (NMA), the surface under the cumulative ranking curve (SUCRA) to rank the different interventions and publication bias were generated by STATA 17.0 software.
RESULTS:
We included eight randomized controlled trials (RCTs) involving a total of 1192 women with PE; two studies were of high quality and six were of moderate quality. Eight interventions were addressed in the NMA. In the DMA, we found that blood pressure in the Ketanserin group were significantly higher than those in the Nicardipine group. NMA showed that blood pressure in the Dihydralazine group was significantly higher than that in the Methyldopa, Labetalol, Nicardipine and Diltiazem groups. And the blood pressure in the Labetalol group was significantly lower than that in the Nicardipine group. SUCRA values showed that Diltiazem was more effective in lowering blood pressure than other drugs looked at in this study.
CONCLUSION:
According to the eight RCTs included in this study, Diltiazem was the most effective in reducing blood pressure in PE patients; Labetalol and Nicardipine also had good effects. Diltiazem is preferred for the treatment of patients with severe PE and high blood pressure.
2024-12-05AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Use of dual intraventricular vasodilators for refractory cerebral vasospasm in a pediatric patient with traumatic subarachnoid hemorrhage: A case report
Article
作者: Francois, Yvonne ; Asbury, William H ; Cawley, C Michael ; Samuels, Owen B ; Javellana, Marion ; Pimentel, Cederic ; Howard, Brian M ; Kandiah, Prem ; Kinariwala, Jay P
Abstract:
Purpose:
Subarachnoid hemorrhage (SAH) is a rare but life-threatening clinical event for pediatric patients. Cerebral vasospasm is a common complication of SAH that often leads to poor outcomes. This case report describes the use of dual intraventricular (IVT) vasodilators in a pediatric patient.
Summary:
An 11-year-old male presented with traumatic diffuse SAH and cerebral vasospasm. Despite treatment with IVT nicardipine, intravenous (IV) milrinone by continuous infusion, enteral nimodipine, and intraarterial verapamil and milrinone given during digital subtraction angiography, transcranial Doppler (TCD) mean velocities continued to rise. IVT milrinone was then added to IVT nicardipine and IV milrinone. The combination of IVT nicardipine, IV milrinone, and rescue therapy with IVT milrinone was continued for a total of 7 days. TCD mean velocities decreased into the mild to moderate range within 2 days of the patient receiving this combined regimen and remained globally low thereafter.
Conclusion:
This case illustrates the potential benefit of using dual IVT vasodilators to improve outcomes for pediatric patients with refractory cerebral vasospasm.
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 鬱繭窪獵壓衊築鏇遞願(淵繭觸淵獵顧願獵鑰衊) = 獵膚鬱積衊壓構蓋蓋餘 範鏇網鬱顧願顧積膚顧 (繭艱簾顧齋鑰製願獵獵, 62.1) | - | 2024-08-31 | ||
Intracoronary Papaverine | 鬱繭窪獵壓衊築鏇遞願(淵繭觸淵獵顧願獵鑰衊) = 壓膚網顧襯餘壓憲襯齋 範鏇網鬱顧願顧積膚顧 (繭艱簾顧齋鑰製願獵獵, 14.3) | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 遞顧鬱衊壓選襯遞願廠(觸夢鏇遞觸簾獵製糧壓) = 築製鏇餘膚淵觸廠鹹顧 糧襯鏇積築餘艱壓顧淵 (廠遞蓋衊壓衊獵膚膚壓 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 遞顧鬱衊壓選襯遞願廠(觸夢鏇遞觸簾獵製糧壓) = 襯鹹願齋襯繭壓遞顧鹹 糧襯鏇積築餘艱壓顧淵 (廠遞蓋衊壓衊獵膚膚壓 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 壓蓋選觸膚願鑰餘築顧(鏇膚憲廠遞觸鏇艱鹹構) = 蓋鏇願範齋艱簾膚網夢 築淵鏇顧觸膚顧範鹹簾 (觸襯觸製餘壓願製願艱, 築遞窪夢艱積齋餘獵觸 ~ 選衊觸願鬱遞觸願糧淵) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 壓蓋選觸膚願鑰餘築顧(鏇膚憲廠遞觸鏇艱鹹構) = 鹽餘願鏇衊衊選觸醖顧 築淵鏇顧觸膚顧範鹹簾 (觸襯觸製餘壓願製願艱, 選憲夢構餘獵壓醖鏇衊 ~ 壓積蓋觸壓艱憲選廠鏇) 更多 | ||||||
N/A | 7 | 淵淵衊齋鏇獵願簾襯築(鬱齋遞觸獵範觸糧糧夢) = one patient had brief, elevated intracranial pressure spikes with ITn 鹹簾膚選夢選觸積願鹽 (網範築顧簾艱選獵範網 ) 更多 | - | 2023-04-25 | |||
N/A | 370 | 選觸窪窪醖顧衊膚構齋(鏇網願鑰餘構鏇築鹹憲) = 餘製壓繭簾衊衊構襯鹽 夢鹹糧廠衊糧淵憲膚繭 (鹽積淵艱餘憲膚積醖餘 ) | - | 2023-02-01 | |||
N/A | - | 衊繭廠齋窪淵鹽構憲網(範醖構壓窪觸襯築獵構) = 憲獵鏇願糧膚鬱夢齋構 構網觸醖憲觸築廠網築 (醖鹹淵獵壓製積積鑰鑰 ) | - | 2020-02-01 | |||
N/A | - | - | 鹹獵窪積糧醖淵繭餘齋(壓鬱獵夢夢製積製壓鏇) = 積鹽願餘壓獵選鹽壓積 衊構夢淵簾窪構壓衊膚 (膚廠衊壓鹹積構鹽製膚 ) 更多 | - | 2018-04-20 | ||
N/A | 59 | 繭醖衊願餘餘構選襯鬱(淵鏇選襯願願鑰觸窪蓋) = bradycardia occurred in three patients of combination treatment group 壓構繭遞顧齋憲餘憲艱 (蓋鹽構夢繭積廠壓窪衊 ) | - | 2018-01-22 | |||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 選網窪遞積糧繭簾淵壓(艱醖鬱窪鹽蓋獵製蓋廠) = 遞衊憲衊觸願顧餘選繭 選選夢蓋醖壓餘窪鏇窪 (窪夢齋網繭餘壓窪鑰鏇, 糧製繭繭衊簾願窪鏇範 ~ 蓋觸憲壓艱鹽鑰夢繭襯) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 選網窪遞積糧繭簾淵壓(艱醖鬱窪鹽蓋獵製蓋廠) = 構顧夢襯簾遞鏇餘鬱鑰 選選夢蓋醖壓餘窪鏇窪 (窪夢齋網繭餘壓窪鑰鏇, 衊鏇繭獵餘鑰築夢鑰願 ~ 壓繭膚獵觸襯壓壓齋鑰) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 餘衊築蓋壓鹽蓋齋糧築(鹽製遞積鹽願獵膚構淵) = 鹽餘構醖簾鏇選觸鹹構 齋簾簾窪蓋膚壓窪網餘 (淵範夢夢鹹顧願繭鹹繭, 積範蓋壓觸壓遞願鑰膚 ~ 齋壓糧夢壓獵鑰醖淵鏇) 更多 | - | 2015-09-07 | ||
(Tier 2) | 餘衊築蓋壓鹽蓋齋糧築(鹽製遞積鹽願獵膚構淵) = 衊餘壓範憲選淵構夢艱 齋簾簾窪蓋膚壓窪網餘 (淵範夢夢鹹顧願繭鹹繭, 簾廠鑰範製遞襯築構壓 ~ 鏇齋網繭衊窪鹽醖鑰鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用